Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues

Core Insights - Humacyte, Inc. has received a U.S. Patent for its bioreactor manufacturing system, which covers key aspects of the production of its lead product, Symvess, providing protection until 2040 [1][2] - Symvess is a first-in-class acellular tissue engineered vessel designed for arterial replacement and repair, manufactured at a commercial scale in a bioprocessing facility [2][5] - The FDA granted full approval for Symvess for use in adults with extremity arterial injuries, allowing for off-the-shelf availability without the need for harvesting veins from patients [3][5] Company Overview - Humacyte is focused on developing bioengineered human tissues and advanced tissue constructs to improve patient outcomes and transform medical practices [5] - The company’s product pipeline includes various applications for vascular trauma repair, hemodialysis access, and other chronic conditions, with ongoing clinical trials and preclinical developments [5] - Humacyte's ATEV has received multiple designations from the FDA, including Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations, highlighting its potential in urgent medical applications [5]